DOCSLIB.ORG

Guideline for the Management of Opioid Induced Constipation in Adults

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guideline for the Management of Opioid Induced Constipation in Adults Guideline for the management of Opioid Induced Constipation in Adults With thanks to Dr Qamar Abbas, Palliative Care Consultant On initiation of an opioid analgesic provide dietary, fluid & exercise advice and co-prescribe a stimulant and softener laxative. Consider bisacodyl or senna (stimulant) and (sodium docusate) laxatives. Review the need for opioids on a regular basis and titrate laxative dose to effective / maximum tolerated dose. The definition of constipation includes the following: For guidelines on the use of opioid medicines for . Infrequent bowel movements (typically three times or fewer per week) pain see Faculty of Pain Medicines . Difficulty during defecation (straining during more than 25% of bowel movements or a http://www.fpm.ac.uk/faculty-of-pain- medicine/opioids-aware subjective sensation of hard stools), or the sensation of incomplete bowel evacuation Any Red Flags present? New onset in elderly, unexplained anaemia, rectal bleeding, positive faecal Refer to 2 week occult blood test, family history of bowel cancer or inflammatory bowel disease, tenesmus, weight loss, Yes wait pathway new/worsening back pain, altered sensation legs, gait disturbance, bladder dysfunction. No Optimise stimulant (bisacodyl or senna) and softener (docusate) laxatives to maximum effective tolerated dose, review once a week. If there is impaction consider an enema. At 2 to 3 weeks if inadequate response, prescribe macrogols, preferred brand Laxido® (1 to 3 sachet day) and consider rectal intervention Discuss with Palliative care team or Bowel & Bladder CNS in community or secondary care if no If partial response with no response / patient discomfort, and consider naldemedine 200microgram daily (preferred choice) significant discomfort to patient, or naloxegol 12.5mg to25 mg daily, see SPC for full prescribing advice. increase the macrogol dose When initiating naldemedine other laxatives can be continued, when initiating naloxegol stop all other laxative treatment until clinical effect is determined. ASSESS AFTER TWO WEEKS Improved in 2 weeks (3 or more spontaneous bowel movements (SBMs) per week and patient feeling comfortable). Continue. Partial response: consider continuing till 4 weeks. Improved in 4 weeks: (3 or more SBMs per week and patient No response: stop and assess other options (discuss with Palliative care team or Bowel and Bladder feeling comfortable). Continue Partial response at 4 weeks, stop or add additional medication. CNS in community or secondary care) No response stop and assess other options (discuss with Palliative care team or Bowel & Bladder CNS in community / secondary care) For palliative care patients naldemedine Patients on naldemedine or naloxegol should be counselled and advised at if they or naloxegol can be initiated by the GP following discussion with and advice develop any sudden severe abdominal pain they should stop taking immediately and let the doctor know. They should also be warned of the potential of opioid withdrawal from a Palliative Care Consultant. Ensure patient is counselled and aware of symptoms which should also be reported to their doctor immediately (can occur hours review process. or days after taking). Opioid induced constipation (OIC) Naldemedine (Rizmoic®) and Naloxegol (Moventig®) are recommended by NICE * within their marketing authorisations, as an option for treating( can OIC occur in adults minutes whose or days constipation after taking has naldemedinenot adequately or responded naloxegol )to laxatives. An inadequate response is defined as opioid-induced constipationAdvise patients symptoms of the of atsymptoms least moderate of opioid severity withdrawal in at least symptoms. 1 of the 4 stool symptom domains (that is, incomplete bowel movement, hard stools, straining or false alarms) while taking at least 1 laxative class for at least 4 days during the prior 2 weeks. From SPCs: Moventig® and Rizmoic® 1.Concomittant use with strong and moderate CYP3A Inducers and inhibitors : see separate SPC for contra -indication guidance and dose adjustment. 2.Contra-indicated in patients with underlying cancer who are at heightened risk of GI perforation, such as: underlying malignancies of GI tract or peritoneum, recurrent or advanced ovarian cancer, vascular endothelial growth factor (VEGF) inhibitor treatment 3. See Moventig SPC for specific cautions with cancer pain NICE TA 345 concluded that taking into account the special warnings highlighted in the SPC its recommendations regarding the use of naloxegol in clinical practice also applies to people with cancer pain who have OIC Oxycodone/naloxone combination (Targinact®)which is not should also be reportedMethylnaltrexone to their doctor is notimmediately to be prescribed. and will NICEnecessitate cannot recommended for prescribing as clinical benefit and economic immediaterecommend discontinuation its use of in naldemedine/naloxegol. OIC as no evidence was submitted and case is not proven – see RED list TA 468 has been withdrawn BNFonline https://bnf.nice.org.uk/treatment-summary/constipation.html , NICE CKS http://cks.nice.org.uk/constipation#!scenario *NICE TA 345 Naloxegol for treating opioid-induced constipation https://www.nice.org.uk/guidance/ta345 *NICE TA 651 Naldemedine for treating opioid-induced constipation https://www.nice.org.uk/guidance/ta651 Approved MOPB Jan 2021 review Jan 2024 Produced MOPB December 2017, Review Dec 20 Next review date Dec 25 .
Load more

Recommended publications
  • Naloxegol (Movantik) Reference Number: ERX.NSMN.02 Effective Date: 07/16 Last Review Date: 03/16
    Clinical Policy: naloxegol (Movantik) Reference Number: ERX.NSMN.02 Effective Date: 07/16 Last Review Date: 03/16 Clinical policies are intended to be reflective of current scientific research and clinical thinking. This policy is current at the time of approval, may be updated and therefore is subject to change. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions. Description The intent of the criteria is to ensure that patients follow selection elements established by Envolve Pharmacy Solutions for the use of naloxegol (MovantikTM). Policy/Criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions that naloxegol (Movantik) is medically necessary for members meeting the following criteria: Initial Approval Criteria: I. Opioid-Induced Constipation (OIC) (must meet all) A. Age is ≥ 18 years old; B. Diagnosis of opioid-induced constipation; C. Member has used an opioid analgesic ≥ 4 weeks; D. Member is not being treated for cancer pain; E. Member has failed ≥ 2 non-bulk forming laxatives (see Table A) from different classes while on opioid therapy, unless contraindicated; F.
    [Show full text]
  • Instruction Sheet: Constipation
    University of North Carolina Wilmington Abrons Student Health Center INSTRUCTION SHEET: CONSTIPATION The Student Health Provider has treated you for constipation. Constipation consists of a change from your usual pattern, with stools becoming less frequent and more difficult to pass. There is no set number of bowel movements a person should have each day or week. People vary widely in frequency of bowel movements, from three times a day to three times a week. Most everyone experiences constipation sometime in his/her life. Certain medicines, such as prescription pain pills, calcium antacids, calcium supplements, antihistamines, diet pills, calcium channel blockers, and diuretics (fluid pills) can cause constipation. Other factors which increase constipation include age, pregnancy, chronic laxative abuse, and a diet low in fiber. Americans, in general, consume a low fiber diet. Fiber acts as a natural laxative: Fiber draws water into the stool and increases the bulk of stools, resulting in softer stools and more rapid movement of stools through the intestine. Fiber in the diet not only minimizes constipation; fiber may prevent diverticulitis, hemorrhoids, intestinal polyps, and even cancer of the bowel. A high fiber diet is also helpful in weight control/reduction. MEASURES WHICH YOU SHOULD TAKE TO HELP TREAT AND PREVENT CONSTIPATION: 1. Drink plenty of fluids every day. Four to six glasses of water or other non-alcoholic beverage help keep stools soft. 2. Exercise daily. Even mild exercise like walking improves bowel function. 3. Consume a diet high in fiber. Fruits, vegetables, whole wheat bread, oatmeal, and bran cereal are all high in fiber.
    [Show full text]
  • Final Stakeholder List PDF 190 KB
    Appendix C NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Naldemedine for treating opioid-induced constipation [ID1189] Matrix of consultees and commentators Consultees Commentators (no right to submit or appeal) Company General • Shionogi (naldemedine) • All Wales Therapeutics and Toxicology Centre Patient/carer groups • Allied Health Professionals Federation • Action on Pain • Board of Community Health Councils in • Black Health Agency Wales • Bladder and Bowel Community • British National Formulary • Bladder and Bowel UK • Care Quality Commission • Cancer Black Care • Department of Health, Social Services • Cancer Equality and Public Safety for Northern Ireland • Guts UK • Healthcare Improvement Scotland • HAWC • Medicines and Healthcare products • Helen Rollason Cancer Charity Regulatory Agency • IBS Network • National Association of Primary Care • Independent Cancer Patients Voice • National Pharmacy Association • Macmillan Cancer Support • NHS Alliance • Maggie’s Centres • NHS Confederation • Marie Curie • Scottish Medicines Consortium • Muslim Council of Britain • Scottish Society of Gastroenterology • Pain Concern • Welsh Health Specialised Services • Pain Relief Foundation Committee • Pain UK • South Asian Health Foundation Possible comparator companies • Specialised Healthcare Alliance • Actavis UK (glycerol suppositories, • Tenovus Cancer Care bisacodyl, lactulose, senna) • Wellbeing of Women • Cardinal Health Martindale Products • Women’s Health Concern (glycerol suppositories) • Concordia International
    [Show full text]
  • 204760Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204760Orig1s000 OTHER REVIEW(S) MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: September 16, 2014 FROM: Julie Beitz, MD SUBJECT: Approval Action TO: NDA 204760 Movantik (naloxegol) tablets AstraZeneca Pharmaceuticals LP Summary Naloxegol is an antagonist of opioid binding at the muͲopioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherallyͲacting opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone and a new molecular entity. Pegylation confers the following properties: naloxegol has reduced passive permeability across membranes compared to naloxone; naloxegol is a PͲglycoprotein (PͲgp) efflux transporter substrate; and naloxegol is orally bioavailable. The reduced passive permeability and PͲgp efflux transporter properties limit CNS entry of naloxegol compared to naloxone. This memo documents my concurrence with the Division of Gastroenterology and Inborn Errors Product’s recommendation for approval of NDA 204760 for Movantik (naloxegol) tablets for the treatment of opioidͲinduced constipation (OIC) in adult patients with chronic nonͲcancer pain. Discussions regarding product labeling, and postmarketing study requirements and commitments have been satisfactorily completed. There are no inspectional issues that preclude approval. Dosing The recommended dose of Movantik (naloxegol) tablets is 25 mg taken once daily in the morning on an empty stomach. Patients who do not tolerate this dose, may reduce the dose to 12.5 mg once daily. Maintenance laxatives should be discontinued prior to initiation of therapy with Movantik.
    [Show full text]
  • Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn
    Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn By © 2018 Solomon Aguta Gisemba Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Dr. Michael Rafferty Dr. Teruna Siahaan Dr. Thomas Tolbert Date Defended: 18 April 2018 The dissertation committee for Solomon Aguta Gisemba certifies that this is the approved version of the following dissertation: Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Date Approved: 10 June 2018 ii Abstract Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 1,2,3 4 8 depression. Arodyn (Ac[Phe ,Arg ,D-Ala ]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the bioactive conformation to give potent and selective analogs. Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of isomerization suppressants were applied to the synthesis of cyclic arodyn analogs.
    [Show full text]
  • Moventig, INN-Naloxegol
    Package leaflet: Information for the patient Moventig 12.5 mg film-coated tablets Moventig 25 mg film-coated tablets naloxegol Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Moventig is and what it is used for 2. What you need to know before you take Moventig 3. How to take Moventig 4. Possible side effects 5. How to store Moventig 6. Contents of the pack and other information 1. What Moventig is and what it is used for Moventig contains the active substance naloxegol. It is a medicine used in adults to treat constipation specifically caused by pain medicines, called opioids, (e.g. morphine, oxycodone, fentanyl, tramadol, codeine) taken on a regular basis. It is used when laxatives have not provided acceptable relief of constipation. Constipation related to opioids can result in symptoms such as: • stomach pain • rectal straining (having to push very hard to move the stool out of the rectum, which can also cause pain in the anus during pushing) • hard stools (stools which are hard “like a rock”) • incomplete emptying of the rectum (after having a bowel movement, the feeling as if a stool is still in the rectum which needs to come out) In patients taking opioids with constipation, who have tried at least one laxative and had incomplete relief of constipation, Moventig has been shown in clinical trials to increase the number of bowel movements and improve symptoms of constipation caused by opioids.
    [Show full text]
  • Medicines That Affect Fluid Balance in the Body
    the bulk of stools by getting them to retain liquid, which encourages the Medicines that affect fluid bowels to push them out. balance in the body Osmotic laxatives e.g. Lactulose, Macrogol - these soften stools by increasing the amount of water released into the bowels, making them easier to pass. Older people are at higher risk of dehydration due to body changes in the ageing process. The risk of dehydration can be increased further when Stimulant laxatives e.g. Senna, Bisacodyl - these stimulate the bowels elderly patients are prescribed medicines for chronic conditions due to old speeding up bowel movements and so less water is absorbed from the age. stool as it passes through the bowels. Some medicines can affect fluid balance in the body and this may result in more water being lost through the kidneys as urine. Stool softener laxatives e.g. Docusate - These can cause more water to The medicines that can increase risk of dehydration are be reabsorbed from the bowel, making the stools softer. listed below. ANTACIDS Antacids are also known to cause dehydration because of the moisture DIURETICS they require when being absorbed by your body. Drinking plenty of water Diuretics are sometimes called 'water tablets' because they can cause you can reduce the dry mouth, stomach cramps and dry skin that is sometimes to pass more urine than usual. They work on the kidneys by increasing the associated with antacids. amount of salt and water that comes out through the urine. Diuretics are often prescribed for heart failure patients and sometimes for patients with The major side effect of antacids containing magnesium is diarrhoea and high blood pressure.
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • Methylnaltrexone Nonf
    Methylnaltrexone Bromide Subcutaneous Injection and Tablets Criteria for Use May 2020 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost- effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES. The Product Information should be consulted for detailed prescribing information. Exclusion Criteria If ANY item below applies, the patient should NOT receive methylnaltrexone subcutaneous injections. Known or suspected mechanical gastrointestinal obstruction or other condition that may compromise drug action or cause bowel dysfunction (e.g., acute abdomen, ostomy, active diverticulitis, ischemic bowel, etc.) Placement of peritoneal catheter for chemotherapy or dialysis (not studied) End-stage renal impairment on dialysis (not studied) Use of methylnaltrexone solely for prevention of opioid-induced constipation or impaction (no supporting evidence). Use of methylnaltrexone for postoperative ileus (preliminary results showed inefficacy). Use of methylnaltrexone for constipation that is not opioid-related (not studied) Concomitant use of other opioid antagonists (potential for increased risks of additive effects and opioid withdrawal) Inclusion Criteria for Opioid-induced Constipation in Adults with Chronic Noncancer Pain All of the following criteria must be fulfilled.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Immediate Hypersensitivity Reactions Caused by Drug Excipients: a Literature Review Caballero ML, Quirce S
    REVIEWS Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review Caballero ML, Quirce S Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain J Investig Allergol Clin Immunol 2020; Vol. 30(2): 86-100 doi: 10.18176/jiaci.0476 Abstract The European Medicines Agency defines excipients as the constituents of a pharmaceutical form apart from the active substance. Immediate hypersensitivity reactions (IHRs) caused by excipients contained in the formulation of medications have been described. However, there are no data on the prevalence of IHRs due to drug excipients. Clinical manifestations of allergy to excipients can range from skin disorders to life-threatening systemic reactions. The aim of this study was to review the literature on allergy to pharmaceutical excipients and to record the IHRs described with various types of medications, specifically reactions due to the excipients contained in their formulations. The cases reported were sorted alphabetically by type of medication and excipient in order to obtain a list of the excipients most frequently involved for each type of medication. Key words: Allergy. Drug immediate hypersensitivity reaction. Excipient. Pharmaceutical excipients. Resumen La Agencia Europea de Medicamentos define los excipientes como los componentes de una forma farmacéutica diferenciados del principio activo. Se han descrito reacciones de hipersensibilidad inmediata causadas por los excipientes contenidos en la formulación de medicamentos. Sin embargo, no hay datos sobre la prevalencia de dichas reacciones. Las manifestaciones clínicas de la alergia a los excipientes pueden ir desde trastornos de la piel hasta reacciones sistémicas que ponen en peligro la vida. El objetivo de este estudio fue realizar una revisión de la literatura sobre la alergia a los excipientes farmacéuticos y recopilar las reacciones inmediatas descritas con diferentes tipos de medicamento, debido solo a excipientes contenidos en sus formulaciones.
    [Show full text]
  • Bowel Management When Taking Pain Or Other Constipating Medicine
    Bowel Management When Taking Pain or Other Constipating Medicine How Medicines Affect Bowel Function Pain medication and some chemotherapy and anti-nausea medicines commonly cause severe constipation. They affect the digestive system by: Slowing down the movement of body waste (stool) in the large bowel (colon). Removing more water than normal from the colon. Preventing Constipation Before taking opioid pain medicine or beginning chemotherapy, it is a good idea to clean out your colon by taking laxatives of your choice. If you have not had a bowel movement for five or more days, ask your nurse for advice on how to pass a large amount of stool from your colon. After beginning treatment, you can prevent constipation by regularly taking stimulant laxatives and stool softeners. These will counteract the effects of the constipating medicines. For example, Senna (a stimulant laxative) helps move stool down in the colon and docusate sodium (a stool softener) helps soften it by keeping water in the stool. Brand names of combination stimulant laxatives and stool softeners are Senna-S® and Senokot-S®. The ‘S’ is the stool softener of these products. You can safely take up to eight Senokot-S or Senna-S pills in generic form per day. Start at the dose advised by your nurse. Gradually increase the dosage until you have soft-formed stools on a regular basis. Do not exceed 500 milligrams (mg) of docusate sodium per day if you are taking the stool softener separate from Senokot-S or Senna-S generic. Stool softeners, stimulant laxatives and combination products can be purchased without a prescription at drug and grocery stores.
    [Show full text]